相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo
Randall J. Brezski et al.
MABS (2014)
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Andrew J. S. Furness et al.
TRENDS IN IMMUNOLOGY (2014)
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Michele De Palma et al.
CANCER CELL (2013)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions
Michelle Kinder et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Fc gamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Jeong M. Kim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs
Anja Lux et al.
JOURNAL OF IMMUNOLOGY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
Katharine D. Grugan et al.
JOURNAL OF IMMUNOLOGY (2012)
Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1
Thomas C. Nesspor et al.
JOURNAL OF MOLECULAR RECOGNITION (2012)
Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314
Ralf Kircheis et al.
MABS (2012)
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Patrick Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
Xuejun Fan et al.
BREAST CANCER RESEARCH (2012)
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Jan Pander et al.
CLINICAL CANCER RESEARCH (2011)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge
Randall J. Brezski et al.
MABS (2011)
Protective and pathogenic functions of macrophage subsets
Peter J. Murray et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Riad Abes et al.
BLOOD (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
Tanja Schneider-Merck et al.
JOURNAL OF IMMUNOLOGY (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Subhra K. Biswas et al.
NATURE IMMUNOLOGY (2010)
Complementing Toll Signaling
Jonathan C. Kagan
SCIENCE SIGNALING (2010)
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a vaccinal effect of rituximab
Shannon P. Hilchey et al.
BLOOD (2009)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
E. Oflazoglu et al.
BRITISH JOURNAL OF CANCER (2009)
Optimization of Fc-mediated effector functions of monoclonal antibodies
William R. Strohl
CURRENT OPINION IN BIOTECHNOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge
Randall J. Brezski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities
Akito Natsume et al.
CANCER RESEARCH (2008)
When binding is enough: nonactivating antibody formats
Aran F. Labrijn et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs
Randall J. Brezski et al.
JOURNAL OF IMMUNOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid
Mary H. Ryan et al.
MOLECULAR IMMUNOLOGY (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Ezogelin Oflazoglu et al.
BLOOD (2007)
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone
Minna Taskinen et al.
CLINICAL CANCER RESEARCH (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Augmented HER-2-Specific immunity during treatment with trastuzumab and chemotherapy
Clare Taylor et al.
CLINICAL CANCER RESEARCH (2007)
CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models
Cam V. Ngo et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection
David O. Beenhouwer et al.
INFECTION AND IMMUNITY (2007)
Antibody therapeutics: isotype and glycoform selection
Roy Jefferis
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Glucocorticoids suppress bone formation via the osteoclast
Hyun-Ju Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor a release by murine macrophages
BC Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The roles of IFNγ in protection against tumor development and cancer immunoediting
H Ikeda et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin
AJH Gearing et al.
IMMUNOLOGY LETTERS (2002)
Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells
LK Ernst et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
